NEW YORK, NY / ACCESSWIRE / July 11, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/oasm.
The investigation concerns whether Oasmiaand certain of its officers and/or directors have violated federal securities laws.
On July 9, 2019, post-market, Oasmia reported that it had terminated its “engagement and cooperation” with former executive chairman Julian Aleksov without further pay, following a tax audit that revealed missing funds connected to suspicious transactions between Oasmia and companies controlled by Aleksov and his former father-in-law. On this news, Oasmia’s American depositary receipt price fell $0.34 per share, or 13.08%, to close at $2.26 per share on July 10, 2019.
If you are aware of any facts relating to this investigation, or purchased Oasmiashares,you can assist this investigation by visiting the firm’s site: www.bgandg.com/oasm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC